Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genital Diseases, Hot Flashes, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Multiple Primary, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, hereditary disease, hereditary neoplastic syndrome, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, multiple endocrine neoplasia, multiple endocrine neoplasia type 1, neoplasm, prostate adenocarcinoma, prostate cancer, prostate carcinoma, prostate disorder	Recruiting	Phase 2	2026-08-17		NCT06957691

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Astellas Pharma US, Inc.	8
Shehzad Basaria, M.D.	1

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Brigham and Women's Hospital	Boston	United States	511